CareCloud, Inc. (CCLD) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended June 30, 2025. CareCloud, Inc. is a healthcare information technology company providing technology-enabled revenue cycle management (RCM), cloud-based software (SaaS), and medical practice management services. The company operates two reportable segments: Healthcare IT and Medical Practice Management. As of June 30, 2025, the company serves approximately 40,000 providers across 2,600 independent medical practices and hospitals.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | YTD 2025 (6 Months) | Q2 2024 (3 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Net Revenue | $27.4 million | $55.0 million | $28.1 million | $54.1 million |
| Operating Income | $3.0 million | $5.0 million | $2.3 million | $2.4 million |
| Net Income | $2.9 million | $4.9 million | $1.7 million | $1.4 million |
| Net Income Attributable to Common | $1.5 million | $0.7 million | $(2.2) million | $(3.8) million |
| Adjusted EBITDA | $6.5 million | $12.1 million | $6.4 million | $10.1 million |
| Cash and Equivalents | $10.4 million | $10.4 million | $2.6 million | $2.6 million |
| Working Capital | $14.9 million | $14.9 million | N/A | N/A |
| Debt (Notes Payable) | $0.3 million | $0.3 million | $0.3 million | $0.3 million |
Note: Preferred stock dividends of $1.4 million (Q2) and $4.2 million (YTD) were deducted to arrive at Net Income Attributable to Common Shareholders.
Material Changes vs. Prior Period
- Revenue: Q2 2025 revenue decreased 3% year-over-year (YoY) to $27.4 million, primarily due to a decline in Medical Practice Management services. However, YTD revenue increased 2% to $55.0 million, driven by growth in Professional Services ($1.1 million increase) and Technology-enabled business solutions ($0.4 million increase).
- Profitability: Operating margin improved significantly to 10.9% in Q2 2025 (up from 8.1% in Q2 2024) and 9.1% YTD (up from 4.4% YTD 2024). This was driven by cost reductions in Selling & Marketing (down 33% Q2) and Restructuring costs (down 80% Q2).
- Capital Structure: In March 2025, the company converted 3.5 million shares of Series A Preferred Stock to common stock, reducing monthly preferred dividend obligations from ~$1.1 million to ~$455,000. This conversion significantly improved net income attributable to common shareholders, turning a loss in Q2 2024 into a profit in Q2 2025.
- Liquidity: Cash balances increased from $5.1 million at year-end 2024 to $10.4 million at June 30, 2025, supported by strong operating cash flow of $12.5 million YTD.
Guidance, Outlook, and Risks
- Outlook: Management expects sufficient liquidity to meet obligations for the next 12 months. The company continues to focus on cost reductions and profitability improvements. The revolving line of credit ($10 million facility) is currently unused, with approximately $9.5 million available, and is set to expire in October 2025 (renewal in process).
- Dividends: Preferred stock dividends, suspended in December 2023, resumed in February 2025. As of June 30, 2025, approximately $7.1 million in dividends remain in arrears (undeclared).
- Acquisitions: The company acquired RevNu Medical Management in April 2025 for contingent consideration of ~$649,000, expanding its audiology and hearing aid billing capabilities.
- Risks:
- Offshore Operations: Significant reliance on offshore offices in Pakistan and Sri Lanka (approx. 18% of total expenses); risks include political instability and lack of deposit insurance for cash held in these jurisdictions.
- Legal Proceedings: Several settled disputes in 2024-2025, but ongoing litigation risks remain regarding contract breaches and service disputes.
- Banking Concentration: Cash balances at Silicon Valley Bank (SVB) exceed FDIC insurance limits.
Investor Verification Checklist
- Preferred Stock Arrears: Verify the status of the $7.1 million in undeclared preferred dividends and the impact of the March 2025 conversion on future cash obligations.
- Revenue Quality: Analyze the decline in Medical Practice Management revenue (down 6% Q2 YoY) versus the growth in Professional Services to understand segment mix shifts.
- Offshore Cash Exposure: Confirm the safety of the $1.2 million held in banks in Pakistan and Sri Lanka, which lack deposit insurance.
- Debt Covenants: Review the upcoming renewal of the $10 million SVB credit line expiring in October 2025 and compliance with adjusted EBITDA covenants.
- Capitalization: Note the significant increase in common shares outstanding (from ~16M to ~42M) due to the preferred stock conversion and its dilutive effect on per-share metrics.